HK1019233A1 - Animal cells and processes for the replication of influenza viruses - Google Patents

Animal cells and processes for the replication of influenza viruses

Info

Publication number
HK1019233A1
HK1019233A1 HK99104226.0A HK99104226A HK1019233A1 HK 1019233 A1 HK1019233 A1 HK 1019233A1 HK 99104226 A HK99104226 A HK 99104226A HK 1019233 A1 HK1019233 A1 HK 1019233A1
Authority
HK
Hong Kong
Prior art keywords
influenza viruses
replication
processes
animal cells
cells
Prior art date
Application number
HK99104226.0A
Other languages
English (en)
Inventor
Albrecht Groner
Jurgen Vorlop
Original Assignee
Novartis Vaccines & Diagnostic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Vaccines & Diagnostic filed Critical Novartis Vaccines & Diagnostic
Publication of HK1019233A1 publication Critical patent/HK1019233A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16151—Methods of production or purification of viral material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Pulmonology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
HK99104226.0A 1996-04-01 1999-09-29 Animal cells and processes for the replication of influenza viruses HK1019233A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19612966A DE19612966B4 (de) 1996-04-01 1996-04-01 MDCK-Zellen und Verfahren zur Vermehrung von Influenzaviren
PCT/IB1997/000403 WO1997037000A1 (fr) 1996-04-01 1997-04-01 Cellules animales et procedes de replication des virus de la grippe

Publications (1)

Publication Number Publication Date
HK1019233A1 true HK1019233A1 (en) 2000-01-28

Family

ID=7790126

Family Applications (1)

Application Number Title Priority Date Filing Date
HK99104226.0A HK1019233A1 (en) 1996-04-01 1999-09-29 Animal cells and processes for the replication of influenza viruses

Country Status (10)

Country Link
US (4) US6455298B1 (fr)
EP (2) EP2275535A1 (fr)
JP (7) JP4243349B2 (fr)
AT (1) ATE482267T1 (fr)
DE (2) DE19612966B4 (fr)
DK (1) DK0904351T3 (fr)
ES (1) ES2352638T3 (fr)
HK (1) HK1019233A1 (fr)
PT (1) PT904351E (fr)
WO (1) WO1997037000A1 (fr)

Families Citing this family (131)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19612966B4 (de) 1996-04-01 2009-12-10 Novartis Vaccines And Diagnostics Gmbh & Co. Kg MDCK-Zellen und Verfahren zur Vermehrung von Influenzaviren
DE19612967A1 (de) * 1996-04-01 1997-10-02 Behringwerke Ag Verfahren zur Vermehrung von Influenzaviren in Zellkultur, sowie die durch das Verfahren erhältlichen Influenzaviren
NZ503827A (en) * 1997-10-25 2001-06-29 Roche Diagnostics Gmbh Suspension packing cell lines for retrovirus vectors
HUP0100538A3 (en) 1997-12-24 2006-01-30 Duphar Int Res Preparation of cells for production of biologicals
ATE473272T1 (de) 2000-03-03 2010-07-15 Chemo Sero Therapeut Res Inst In serumfreier kultur verwendbare zelle, kultursuspension und verfahren zur virusproduktion als impfstoff unter verwendung der zelle
JP3547715B2 (ja) * 2001-03-06 2004-07-28 榮 新垣 ベクター精製用装置及び方法
DE10144903A1 (de) * 2001-09-12 2003-03-27 Chiron Behring Gmbh & Co Vermehrung von Viren in Zellkultur
DE10144906B4 (de) * 2001-09-12 2013-11-28 Novartis Vaccines And Diagnostics Gmbh Verfahren zur großtechnischen Herstellung von Impfstoffen
US20030078471A1 (en) * 2001-10-18 2003-04-24 Foley Frederick J. Manipulation of an organ
US6951752B2 (en) * 2001-12-10 2005-10-04 Bexter Healthcare S.A. Method for large scale production of virus antigen
US7465456B2 (en) 2002-04-26 2008-12-16 Medimmune, Llc Multi plasmid system for the production of influenza virus
DK1499348T3 (en) * 2002-04-26 2015-01-05 Medimmune Llc PROCEDURE FOR PREPARING INFECTIOUS INFLUENZA B-VIRA IN CELL CULTURE
US20060110406A1 (en) * 2003-02-25 2006-05-25 Medimmune Vaccines, Inc. Refrigerator-temperature stable influenza vaccine compositions
CA2517181C (fr) * 2003-02-25 2013-07-16 Medimmune Vaccines, Inc. Procedes de production de compositions vaccinales contre la grippe
DE602004028736D1 (de) * 2003-06-20 2010-09-30 Microbix Biosystems Inc Verbesserungen bei der virusproduktion
WO2005026333A1 (fr) * 2003-09-09 2005-03-24 Japan Science And Technology Agency Technique de culture en suspension de cellules adherentes a l'aide de proteases et methode de production d'un virus utilisant les cellules comme hotes
ATE469972T1 (de) 2003-12-23 2010-06-15 Medimmune Llc Multiplasmid-system zur erzeugung des grippevirus
CA2559371C (fr) 2004-03-09 2014-07-08 Chiron Corporation Vaccins antigrippaux
JP2007530680A (ja) * 2004-04-01 2007-11-01 アルザ・コーポレーシヨン インフルエンザワクチンの経皮デリバリーのための装置および方法
EP1747268A1 (fr) * 2004-05-20 2007-01-31 ID Biomedical Corporation Procédé pour la fabrication d'un vaccin contre la grippe
WO2006027698A1 (fr) 2004-09-09 2006-03-16 Novartis Vaccines And Diagnostics Gmbh & Co Kg. Reduction de risques iatrogenes potentiels associes aux vaccins contre la grippe
ES2633471T3 (es) 2004-10-06 2017-09-21 Medimmune, Llc Composiciones de vacuna contra la gripe estables a temperatura de refrigerador
DE102004049290A1 (de) * 2004-10-09 2006-04-20 Bayer Healthcare Ag Verfahren zur Herstellung von Virusmaterial
EP2923711A1 (fr) 2004-11-03 2015-09-30 Novartis Vaccines and Diagnostics, Inc. Vaccin contre la grippe
JP5085336B2 (ja) 2004-12-08 2012-11-28 メディミューン，エルエルシー インフルエンザワクチン組成物の製造方法
KR101323459B1 (ko) 2004-12-23 2013-10-29 메디뮨 엘엘씨 바이러스의 증식을 위한 비종양형성성 ｍｄｃｋ 세포주
US7572620B2 (en) 2005-01-11 2009-08-11 Wisconsin Alumni Research Foundation H3 equine influenza A virus
FR2884255B1 (fr) * 2005-04-11 2010-11-05 Vivalis Utilisation de lignees de cellules souches aviaires ebx pour la production de vaccin contre la grippe
US20070111309A1 (en) * 2005-10-04 2007-05-17 Daelli Marcelo G Vero cell line adapted to grow in suspension
CN104474543A (zh) 2005-11-01 2015-04-01 诺华疫苗和诊断有限两合公司 经由β-丙内酯处理的残留细胞DNA水平降低的细胞衍生病毒疫苗
NZ568211A (en) 2005-11-04 2011-11-25 Novartis Vaccines & Diagnostic Influenza vaccines including combinations of particulate adjuvants and immunopotentiators
JP2009514850A (ja) 2005-11-04 2009-04-09 ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル アジュバントとして減少した量の水中油型エマルションを有するインフルエンザワクチン
NZ592713A (en) 2005-11-04 2012-12-21 Novartis Vaccines & Diagnostic Adjuvanted influenza vaccines including a cytokine-inducing agents other than an agonist of Toll-Like Receptor 9
KR20080069232A (ko) 2005-11-04 2008-07-25 노바티스 백신즈 앤드 다이아그노스틱스 에스.알.엘. 스플리트 인플루엔자 백신에 대한 보조제로서 유리 수성상계면활성제를 갖는 에멀젼
EP2368572B1 (fr) 2005-11-04 2020-03-04 Seqirus UK Limited Vaccins avec adjuvants dotés d'antigènes non virioniques préparés à partir de virus de la grippe cultivés dans une culture cellulaire
KR20110110853A (ko) * 2006-01-27 2011-10-07 노파르티스 파르마 아게 적혈구응집소 및 기질 단백질을 함유한 인플루엔자 백신
US20100068223A1 (en) * 2006-03-24 2010-03-18 Hanno Scheffczik Storage of Influenza Vaccines Without Refrigeration
AU2007245192B2 (en) 2006-03-31 2012-04-12 Wisconsin Alumni Research Foundation High titer recombinant influenza viruses for vaccines
EP2022849A4 (fr) * 2006-05-11 2010-10-06 Chemo Sero Therapeut Res Inst Procédé permettant une prolifération du virus de la grippe
GB0614460D0 (en) 2006-07-20 2006-08-30 Novartis Ag Vaccines
CA3016948A1 (fr) 2006-09-11 2008-03-20 Seqirus UK Limited Fabrication de vaccins contre le virus grippal sans utiliser d'oeufs
SG174813A1 (en) 2006-09-15 2011-10-28 Medimmune Llc Mdck cell lines supporting viral growth to high titers and bioreactor process using the same
PL2121011T3 (pl) 2006-12-06 2014-10-31 Novartis Ag Szczepionki zawierające antygeny czterech szczepów wirusa grypy
US8673613B2 (en) * 2007-06-18 2014-03-18 Medimmune, Llc Influenza B viruses having alterations in the hemaglutinin polypeptide
US9474798B2 (en) 2007-06-18 2016-10-25 Wisconsin Alumni Research Foundation Influenza M2 protein mutant viruses as live influenza attenuated vaccines
EA201070066A1 (ru) * 2007-06-27 2010-06-30 Новартис Аг Вакцины против гриппа с низким содержанием добавок
US20090042253A1 (en) * 2007-08-09 2009-02-12 Wyeth Use of perfusion to enhance production of fed-batch cell culture in bioreactors
GB0810305D0 (en) 2008-06-05 2008-07-09 Novartis Ag Influenza vaccination
WO2009081172A1 (fr) 2007-12-24 2009-07-02 Novartis Ag Dosages pour vaccins adsorbés contre la grippe
US8506966B2 (en) 2008-02-22 2013-08-13 Novartis Ag Adjuvanted influenza vaccines for pediatric use
EP2268309B1 (fr) 2008-03-18 2015-01-21 Novartis AG Améliorations dans la préparation des antigènes pour le vaccin contre le virus de la grippe
TW201012930A (en) 2008-06-16 2010-04-01 Intervet Int Bv Method of replicating viruses in suspension
CA2733356C (fr) 2008-08-01 2016-06-07 Gamma Vaccines Pty Limited Vaccins contre la grippe
RU2015103990A (ru) 2008-09-24 2015-10-27 Медиммун, Ллк Способы культивирования клеток, размножения и очистки вирусов
US8785173B2 (en) 2008-09-24 2014-07-22 Medimmune, Llc Methods for purification of viruses
WO2010079081A1 (fr) 2009-01-07 2010-07-15 Glaxosmithkline Biologicals S.A. Procédés de récupération d'un virus ou d'un antigène viral produit par culture cellulaire
EP2393922A1 (fr) 2009-02-06 2011-12-14 GlaxoSmithKline Biologicals S.A. Nouveau de purification de virus ou d'antigènes viraux par ultracentrifugation sur gradient de densité
CA2752039A1 (fr) 2009-02-10 2010-08-19 Novartis Ag Regimes de vaccin antigrippal pour souches liees a une pandemie
EA201500910A1 (ru) 2009-02-10 2016-04-29 Новартис Аг Вакцины против гриппа со сниженным количеством сквалена
WO2010092477A1 (fr) 2009-02-10 2010-08-19 Novartis Ag Vaccins contre l'influenza possédant des quantités accrues d'antigène h3
DE102010018462A1 (de) 2009-04-27 2011-04-07 Novartis Ag Impfstoffe zum Schutz gegen Influenza
NZ596296A (en) 2009-05-08 2013-08-30 Novartis Ag Generic assays for detection of influenza viruses
CN102597246B (zh) 2009-05-21 2014-02-26 诺华股份有限公司 使用非内源pol I启动子的反向遗传
NZ596671A (en) 2009-05-29 2013-06-28 Novartis Ag Assays for influenza virus hemagglutinins
EP2459722B1 (fr) 2009-07-31 2017-09-06 Seqirus UK Limited Systemes de genetique inverse
CN102695523A (zh) 2009-09-10 2012-09-26 诺华有限公司 针对呼吸道疾病的组合疫苗
CA2778332A1 (fr) * 2009-10-20 2011-04-28 Novartis Ag Procedes genetiques inverses ameliores pour le sauvetage de virus
ES2813347T3 (es) 2009-10-26 2021-03-23 Wisconsin Alumni Res Found Virus recombinantes de la influenza de alto título con replicación mejorada en células Vero
DE102009056883B4 (de) 2009-12-03 2012-08-16 Novartis Ag Impfstoff-Adjuvantien und verbesserte Verfahren zur Herstellung derselben
JP5820390B2 (ja) 2009-12-03 2015-11-24 ノバルティス アーゲー エマルジョンの微小流動化中および／または均質化中における成分の循環
DE102009056871A1 (de) 2009-12-03 2011-06-22 Novartis AG, 4056 Impfstoff-Adjuvantien und verbesserte Verfahren zur Herstellung derselben
PL2380558T5 (pl) 2009-12-03 2020-10-05 Novartis Ag Wytwarzanie emulsji w układzie komory oddziaływań i komory przeciwciśnieniowej do mikrofluidyzacji
MX2012005598A (es) 2009-12-03 2012-05-29 Novartis Ag Filtracion hidrofilica durante la fabricacion de adyuvantes de vacuna.
DE102009056884B4 (de) 2009-12-03 2021-03-18 Novartis Ag Impfstoff-Adjuvantien und verbesserte Verfahren zur Herstellung derselben
US20120309056A1 (en) 2010-02-04 2012-12-06 Leon Arnaud Fed-batch process using concentrated cell culture medium for the efficient production of biologics in eb66 cells
EP2545172B2 (fr) 2010-03-08 2017-12-06 Novartis AG Méthode de recherche de pathogènes intracellulaires
US10130697B2 (en) 2010-03-23 2018-11-20 Wisconsin Alumni Research Foundation (Warf) Vaccines comprising mutant attenuated influenza viruses
CA2797059A1 (fr) 2010-05-03 2011-11-10 Glaxosmithkline Biologicals S.A. Nouveau procede
CN102946727B (zh) 2010-05-06 2015-08-19 诺华有限公司 微生物灭活的有机过氧化物化合物
ES2453316T5 (es) 2010-05-12 2017-07-18 Novartis Ag Procedimientos mejorados para preparar escualeno
CA2800150C (fr) 2010-05-21 2018-09-04 Novartis Ag Procede de rearrangement des genes du virus grippal
DK2575872T3 (da) 2010-06-01 2020-10-19 Seqirus Uk Ltd Koncentrering af influenzavaccineantigener uden frysetørring
AU2011262312B2 (en) 2010-06-01 2015-05-28 Novartis Ag Concentration and lyophilization of influenza vaccine antigens
US20130344569A1 (en) * 2010-08-16 2013-12-26 Cevec Pharmaceuticals Gmbh Permanent human cell lines for the production of influenza viruses
US9051361B2 (en) 2010-08-17 2015-06-09 National Health Research Institutes Immunogenic compositions and uses thereof
CA2808965C (fr) 2010-08-20 2020-01-07 Novartis Ag Ensembles d'aiguilles solubles pour l'administration de vaccins contre la grippe
AU2011300402B2 (en) 2010-09-07 2015-01-22 Novartis Ag Generic assays for detection of mammalian reovirus
US20140079732A1 (en) 2011-01-27 2014-03-20 Gamma Vaccines Pty Limited Combination vaccines
EP2678452B1 (fr) 2011-02-25 2016-02-24 Novartis AG Témoin positif interne exogène pour détection de virus
GB201216121D0 (en) 2012-09-10 2012-10-24 Novartis Ag Sample quantification by disc centrifugation
CA2852857A1 (fr) 2011-10-20 2013-04-25 Novartis Ag Vaccins avec adjuvant contre le virus grippal b pour primo-vaccination pediatrique
ES2564138T3 (es) 2011-12-12 2016-03-18 Novartis Ag Ensayo para Hemaglutinina del virus de la influenza
AU2014203051C1 (en) * 2012-03-02 2016-09-01 Seqirus UK Limited Influenza Virus Reassortment
WO2013087945A2 (fr) * 2012-03-02 2013-06-20 Novartis Ag Réassortiment du virus de la grippe
CA2866465A1 (fr) 2012-03-06 2013-09-12 Crucell Holland B.V. Vaccination amelioree contre la grippe
JP6152535B2 (ja) * 2012-04-16 2017-06-28 公益財団法人ヒューマンサイエンス振興財団 細胞培養組成物及びインフルエンザウイルスの生産方法
JP2015526062A (ja) 2012-06-04 2015-09-10 ノバルティス アーゲー 改善された安全性試験
GB201218195D0 (en) 2012-10-10 2012-11-21 Istituto Zooprofilattico Sperimentale Delle Venezie Composition
WO2014086732A2 (fr) 2012-12-03 2014-06-12 Novartis Ag Réassortiment du virus de la grippe
MX2015011529A (es) 2013-03-13 2016-02-05 Novartis Ag Reordenamiento del virus de infuenza b.
US20140335116A1 (en) 2013-05-10 2014-11-13 Novartis Ag Avoiding narcolepsy risk in influenza vaccines
DE202013005130U1 (de) 2013-06-05 2013-09-10 Novartis Ag Influenza Virus Reassortierung
DE202013005100U1 (de) 2013-06-05 2013-08-26 Novartis Ag Influenza Virus Reassortierung
WO2014195920A2 (fr) 2013-06-06 2014-12-11 Novartis Ag Réassortiment du virus de la grippe
KR101370512B1 (ko) * 2013-06-07 2014-03-06 재단법인 목암생명공학연구소 무단백 배지에서 부유 배양되는 mdck 유래 세포주 및 상기 세포주를 이용하여 바이러스를 증식시키는 방법
EP3022296B1 (fr) 2013-07-15 2022-12-28 Wisconsin Alumni Research Foundation Virus influenza recombinés à titre élevé avec augmentation de la réplication dans les oeufs ou les cellules de la lignée vero ou mdck
JP6851827B2 (ja) 2013-08-30 2021-03-31 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 細胞培養中でのウイルスの大規模製造
JP6373376B2 (ja) 2013-11-15 2018-08-15 ノバルティス アーゲー 残留細胞培養不純物の除去
TW202204596A (zh) 2014-06-06 2022-02-01 美商健臻公司 灌注培養方法及其用途
TW202246486A (zh) * 2014-06-09 2022-12-01 美商健臻公司 種子罐培養法(seed train processes)及其用途
WO2015196150A2 (fr) 2014-06-20 2015-12-23 Wisconsin Alumni Research Foundation (Warf) Mutations conférant une stabilité génétique à des gènes supplémentaires dans des virus de la grippe
AU2015252119A1 (en) 2014-11-07 2016-05-26 Takeda Vaccines, Inc. Hand, foot, and mouth vaccines and methods of manufacture and use thereof
AR102547A1 (es) 2014-11-07 2017-03-08 Takeda Vaccines Inc Vacunas contra la enfermedad de manos, pies y boca y métodos de fabricación y su uso
ES2861806T3 (es) 2014-12-02 2021-10-06 Novartis Ag Fabricación de composiciones que contienen tensioactivo
US10633422B2 (en) 2015-06-01 2020-04-28 Wisconsin Alumni Research Foundation (Warf) Influenza virus replication by inhibiting microRNA lec7C binding to influenza viral cRNA and mRNA
JP2018524323A (ja) 2015-06-26 2018-08-30 セキラス ユーケー リミテッド 抗原がマッチしたインフルエンザワクチン
US9890363B2 (en) 2015-07-06 2018-02-13 Wisconsin Alumni Research Foundation (Warf) Influenza virus replication for vaccine development
EP3764098B1 (fr) 2015-07-07 2022-11-16 Seqirus UK Limited Dosage de la puissance de la grippe
TWI781915B (zh) 2015-10-30 2022-11-01 財團法人國家衛生研究院 用於疫苗製備之於無血清、化學性界定培養基中之mdck懸浮細胞株
EP3417056A1 (fr) 2016-02-19 2018-12-26 Wisconsin Alumni Research Foundation (WARF) Réplication améliorée du virus de la grippe b pour l'élaboration de vaccin
AU2017244758B2 (en) 2016-03-29 2022-08-25 The Research Foundation For Microbial Diseases Of Osaka University Method for culturing MDCK cells
JP2017038622A (ja) * 2016-11-21 2017-02-23 ウィスコンシン アルムニ リサーチ ファンデイション Ｈ３型ウマａ型インフルエンザウイルス
AU2018359556B2 (en) 2017-11-03 2021-12-02 Takeda Vaccines, Inc. Zika vaccines and immunogenic compositions, and methods of using the same
WO2020167432A2 (fr) 2019-01-23 2020-08-20 Yoshihiro Kawaoka Mutations conférant une stabilité génétique à des gènes supplémentaires dans des virus de la grippe
CN113874496A (zh) 2019-02-08 2021-12-31 威斯康星校友研究基金会(Warf) 人源化细胞系
US11390649B2 (en) 2019-05-01 2022-07-19 Wisconsin Alumni Research Foundation (Warf) Influenza virus replication for vaccine development
WO2020226831A1 (fr) 2019-05-08 2020-11-12 Takeda Vaccines, Inc. Compositions de virus inactivé et formulations de vaccin à base de zika
EP4022046A2 (fr) 2019-08-27 2022-07-06 Wisconsin Alumni Research Foundation (WARF) Virus de la grippe recombinants à ha stabilisé pour réplication dans des oeufs
JP2023502650A (ja) 2019-11-18 2023-01-25 セキラス ピーティーワイ リミテッド 遺伝子再集合インフルエンザウイルスを産生するための方法
JP2023532944A (ja) 2020-06-30 2023-08-01 セキラス ユーケー リミテッド 水中油型エマルジョンアジュバントの低温濾過
WO2023154043A1 (fr) 2022-02-09 2023-08-17 Takeda Vaccines, Inc. Vaccins contre le zika et compositions immunogènes, et procédés d'utilisation associés

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1278075B (de) * 1964-06-22 1968-09-19 Norden Lab Inc Verwendung von Gewebekulturen zur Zuechtung von Viren fuer die Gewinnung von Impfstoffen
US3616203A (en) * 1969-12-11 1971-10-26 Norden Lab Inc Virus culture and method
US4064232A (en) 1974-01-14 1977-12-20 Sandoz Ltd. Process for isolating the immunogenic components of influenza viruses
CA1122527A (fr) 1979-05-15 1982-04-27 Karen K. Brown Production d'un vaccin contre l'influenza par culture de cellules en milieu liquide
USRE33164E (en) * 1979-05-15 1990-02-13 Mobay Corporation Influenza vaccine production in liquid cell culture
US4500513A (en) * 1979-05-15 1985-02-19 Miles Laboratories, Inc. Influenza vaccine production in liquid cell culture
US5013663A (en) * 1983-06-15 1991-05-07 American Home Products Corporation Canine corona virus vaccine
US4783411A (en) 1984-10-22 1988-11-08 Janis Gabliks Influenza-A virus vaccine from fish cell cultures
EP0389925B1 (fr) 1989-03-29 1995-12-27 The Research Foundation Of State University Of New York Méthode de purification d'une protéine de membrane externe d'Haemophilus influenzae
JP2827298B2 (ja) * 1989-07-10 1998-11-25 三菱化学株式会社 細胞培養担体
AT393277B (de) 1990-01-04 1991-09-25 Immuno Ag Verfahren zur herstellung von fruehsommer- meningoenzephalitis-virus (fsme-virus)-antigen
JPH0420284A (ja) * 1990-05-12 1992-01-23 Mitsubishi Kasei Corp 細胞培養用マイクロキャリア
JPH05207873A (ja) * 1992-01-27 1993-08-20 Mitsubishi Kasei Corp 付着性動物細胞の培養方法
US5762939A (en) * 1993-09-13 1998-06-09 Mg-Pmc, Llc Method for producing influenza hemagglutinin multivalent vaccines using baculovirus
US5756341A (en) * 1994-11-10 1998-05-26 Immuno Ag Method for controlling the infectivity of viruses
US5753489A (en) * 1994-11-10 1998-05-19 Immuno Ag Method for producing viruses and vaccines in serum-free culture
DE69535940D1 (de) 1994-11-10 2009-06-04 Baxter Healthcare Sa Verfahren zur Herstellung von biologischen Produkten in Protein-freiem Kultur
JPH11509081A (ja) 1994-11-16 1999-08-17 セント ジュード チルドレンズ リサーチ ホスピタル 新規の複製プロセス
US5646033A (en) * 1994-11-30 1997-07-08 Dyncorp African green monkey kidney cell lines useful for maintaining viruses and for preparation of viral vaccines
AU712213B2 (en) 1995-09-22 1999-11-04 Connaught Laboratories Limited Parainfluenza virus glycoproteins and vaccines
DE19612966B4 (de) 1996-04-01 2009-12-10 Novartis Vaccines And Diagnostics Gmbh & Co. Kg MDCK-Zellen und Verfahren zur Vermehrung von Influenzaviren
DE19612967A1 (de) 1996-04-01 1997-10-02 Behringwerke Ag Verfahren zur Vermehrung von Influenzaviren in Zellkultur, sowie die durch das Verfahren erhältlichen Influenzaviren
US6514502B1 (en) * 1999-01-26 2003-02-04 Schering-Plough Veterinary Corporation Propagation of bovine cononavirus in chinese hamster ovary cells

Also Published As

Publication number Publication date
ATE482267T1 (de) 2010-10-15
EP2275535A1 (fr) 2011-01-19
US6455298B1 (en) 2002-09-24
DE19612966B4 (de) 2009-12-10
EP0904351A1 (fr) 1999-03-31
US6656720B2 (en) 2003-12-02
DE69740002D1 (de) 2010-11-04
JP2000507448A (ja) 2000-06-20
JP2012005502A (ja) 2012-01-12
ES2352638T3 (es) 2011-02-22
US20050202553A1 (en) 2005-09-15
JP2006230415A (ja) 2006-09-07
JP2005211080A (ja) 2005-08-11
JP2012016358A (ja) 2012-01-26
DK0904351T3 (da) 2010-11-01
JP4243349B2 (ja) 2009-03-25
US20030073223A1 (en) 2003-04-17
PT904351E (pt) 2010-12-28
US20080274141A1 (en) 2008-11-06
EP0904351B1 (fr) 2010-09-22
WO1997037000A1 (fr) 1997-10-09
DE19612966A1 (de) 1997-10-02
JP2004331673A (ja) 2004-11-25
JP2009034115A (ja) 2009-02-19

Similar Documents

Publication Publication Date Title
HK1019233A1 (en) Animal cells and processes for the replication of influenza viruses
HK1142093A1 (en) Process for the replication of influenza viruses in cell culture, and the influenza viruses obtainable by the process
UA42089C2 (uk) Протигрипозна вакцина на основі поверхневого антигену, спосіб її виробництва
ATE399855T1 (de) Tierzellkulturmedium mit pflanzlichen nährstoffen
EA200200604A1 (ru) Производство вакцин
IL192762A0 (en) Method for identifying cell differentiation factors
BRPI0407636A (pt) meio de cultura de células, linhagem de células animais, métodos para produzir um meio de cultura condicionado, células animais, uma cultura de células animais, vìrus em uma cultura de células animais, ou, de preferência, humanas diplóides dependentes de ancoragem, método para produzir uma vacina, e, população de vìrus
DK1155116T3 (da) Anvendelse af kollagenase i fremstillingen af kulturer af neurale stamceller
DE69626022D1 (de) Verfahren zur industriellen herstellung eines japanischen enkephalitis impfstoffes, und so erhaltener impfstoff
EP1077599A4 (fr) TRANSFORMATION DE $i(BRASSICA) PAR BOMBARDEMENT DE PARTICULES
WO1999029279A3 (fr) Survie a long terme et regeneration de neurones du systeme nerveux central
ES8104405A1 (es) Procedimiento para preparar una vacuna de virus de gripe
WO1998036636A3 (fr) Procede de production de cultures cellulaires embryogenes pour la production de bananes transgeniques (de l'espece musa)
HU9202009D0 (en) Matrix with adherently bound cells and method for producing viruses and antigens thereof
CA2250714A1 (fr) Cellules animales et procedes de replication des virus de la grippe
AU583795B2 (en) Process for the maintenance and proliferation of virus genomes and derivatives thereof
ES2052883T3 (es) Cultivo de celulas de riñon de cerdo y su uso en la produccion de vacunas.
AU584774B2 (en) Process for regenerating corn
DK1238057T3 (da) Fremgangsmåde til produktion af vedhæftende dyreceller
AU6262786A (en) Growing aids virus in cell lines lacking human class ii histocompatability antigens
Gen et al. Enhancement of Growth of Bluetongue Viruses in Cell Cultures through Trypsin Treatment
BRPI0002694C1 (pt) processo de obtenção de vacina contra raiva em células vero, para uso humano
JPS5765184A (en) Stable immobilized adenylate kinase composite and its preparation

Legal Events

Date Code Title Description
PE Patent expired

Effective date: 20170331